Drug Type Small molecule drug |
Synonyms + [3] |
Target |
Mechanism α-synuclein inhibitors(Synuclein alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H31N5OS |
InChIKeyGDFWCSZNQVAQGR-GOSISDBHSA-N |
CAS Registry1802518-92-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Phase 2 | GB | 30 Dec 2020 | |
Parkinson Disease | Phase 2 | FR | 30 Dec 2020 | |
Parkinson Disease | Phase 2 | PL | 30 Dec 2020 | |
Parkinson Disease | Phase 2 | ES | 30 Dec 2020 | |
Parkinson Disease | Phase 2 | DE | 30 Dec 2020 | |
Parkinson Disease | Phase 2 | US | 30 Dec 2020 | |
Parkinson Disease | Phase 2 | CA | 30 Dec 2020 | |
Parkinson Disease | Phase 2 | IT | 30 Dec 2020 | |
Parkinson Disease | Phase 2 | NL | 30 Dec 2020 |
Phase 1 | ASYN misfolding | 4 | cebzajcpjg(ohdruxtaxu) = Treatment-emergent adverse events (TEAEs) were reported by 75% (n = 3) of participants. No drug-related TEAEs, deaths, serious adverse events, or discontinuations were reported. ggalkzlsdy (newjbkebkc ) | Positive | 01 Apr 2024 |